In Minnesota and throughout the country, many lives have been devastated by an often fatal form of cancer that attacks the lining of the lungs. Most patients who have mesothelioma contracted the disease through exposure to asbestos. A new treatment is showing great promise to help those who are in the advanced stages of this disease.
People diagnosed with mesothelioma typically survive one to two years after diagnosis. Because symptoms usually remain hidden for years, diagnosis often is not made until a person is already in the late stages of illness. Transarterial Chemoperfusion (TACP) is said to be a safer and more effective form of treatment than traditional methods for those suffering from mesothelioma.
TACP may also help improve quality of life for patients who might otherwise have few options left. The treatment focuses on delivering chemotherapy agents to the internal mammary artery. This artery supplies blood to diseased lung tissue. In a phase II clinical study, TACP showed a 70% disease control rate and was also tolerated well by the patients who received treatment.
Many Minnesota families have encountered serious financial distress as they do their best to care for loved ones who have been diagnosed with mesothelioma. Sadly, many victims of asbestos exposure have later learned that their illnesses were likely preventable were it not for employer negligence in providing necessary training, information and equipment to keep them safe in the workplace. In many cases, such issues have prompted litigation. This type of litigation is stressful and complex, which is why most people choose to rely on experienced legal advocates to represent them in court.
